COVID Treatment Options

The FDA has issued emergency use authorization (EUA) for Molnupiravir and Paxlovid for the treatment of mild-to-moderate COVID-19.

Having new drugs that help reduce COVID hospitalizations and deaths is obviously wonderful news, but in no way is it a substitute for getting vaccinated and boosted. Preventing illness in the first place is always better than getting sick and then getting treated.



FDA Emergency Use Authorization Letter
FDA Emergency Use Authorization Announcement
Fact Sheet for Healthcare Providers
Fact Sheet for Caregivers and Patients
Paxlovid effectiveness (British Medical Journal)

For Providers

Patient Prioritization for COVID-19 Therapeutics (DHHS)

Molnupiravir Paper Order Form

Paxlovid Paper Order Form


The Centers for Disease Control and Prevention (CDC) Nowcast data from April 5, 2022,  estimates that the proportion of COVID-19 cases caused by the Omicron BA.2 variant is above 50% in all Health and Human Services (HHS) U.S. regions. Data included in the health care provider fact sheet show the authorized dose of sotrovimab is unlikely to be effective against the BA.2 sub-variant. Due to these data, sotrovimab is not authorized in any U.S. state or territory at this time.

Health care providers should use other approved or authorized products as they choose appropriate treatment options for patients.